China Biologic Products (NASDAQ:CBPO) Issues Earnings Results

Share on StockTwits

China Biologic Products (NASDAQ:CBPO) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.52, RTT News reports. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The business had revenue of $136.10 million for the quarter. During the same quarter in the previous year, the business earned $0.96 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis.

Shares of CBPO traded up $0.43 during trading hours on Wednesday, hitting $115.73. The company had a trading volume of 100,800 shares, compared to its average volume of 178,334. The firm has a market cap of $4.57 billion, a P/E ratio of 28.79, a P/E/G ratio of 7.05 and a beta of 1.18. The stock’s 50 day moving average price is $115.03 and its 200 day moving average price is $100.82. China Biologic Products has a 52-week low of $69.22 and a 52-week high of $117.68.

A number of research firms have weighed in on CBPO. Zacks Investment Research downgraded China Biologic Products from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. BidaskClub downgraded China Biologic Products from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, ValuEngine upgraded China Biologic Products from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $92.67.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Read More: What is the Bid-Ask Spread?

Earnings History for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Automatic Data Processing  Expected to Announce Quarterly Sales of $3.68 Billion
Automatic Data Processing Expected to Announce Quarterly Sales of $3.68 Billion
Mobius  Price Hits $0.0049 on Exchanges
Mobius Price Hits $0.0049 on Exchanges
EOS Hits Market Capitalization of $2.59 Billion
EOS Hits Market Capitalization of $2.59 Billion
NEO  Reaches 1-Day Volume of $331.81 Million
NEO Reaches 1-Day Volume of $331.81 Million
USDX  Hits 1-Day Volume of $115.00
USDX Hits 1-Day Volume of $115.00
Analysts Expect Capital Southwest Co.  Will Post Quarterly Sales of $15.61 Million
Analysts Expect Capital Southwest Co. Will Post Quarterly Sales of $15.61 Million


 
© 2006-2019 Zolmax.